Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.58 |
| ▸ | HTR3B | O95264 | 2/20 | 0.58 |
| ▸ | HTR3A | P46098 | 2/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.58 |
| ▸ | PIM1 | P11309 | 3/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13193690 | 0.87 | HTR3E (0.55) | ALDH1A1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13362485 | 0.84 | PDE10A (0.55) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL14818715 | 0.84 | PDE10A (0.59) | PDE10A | |
| SCHEMBL13751510 | 0.83 | HTR3E (0.58) | ALDH1A1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL25189276 | 0.83 | HTR3E (0.58) | ALDH1A1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL10233469 | 0.83 | PDE10A (0.57) | PDE10A | |
| SCHEMBL13171621 | 0.83 | HTR3E (0.54) | ALDH1A1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14618026 | 0.81 | HTR3A (0.62) | ALDH1A1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL10272910 | 0.80 | PDE10A (0.53) | ALDH1A1KDM4EHTTPDE10AHPGD | |
| SCHEMBL17993354 | 0.79 | OGA (0.48) | ALDH1A1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-8841455-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2011079076-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| CN-100422181-C | [1,8] naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-101189237-A | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2008-05-28 | — | — | CN | disclosed |
| EP-1869041-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2006-10-19 | — | — | US | disclosed |
| WO-2006103559-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| CN-1839134-A | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2006-09-27 | — | — | CN | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | ALDH1A1 1148/4885HTR3E 1510/4885HTR3B 1000/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | ALDH1A1 3523/4885HTR3E 2136/4885HTR3B 2505/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | ALDH1A1 1148/4885HTR3E 1510/4885HTR3B 1000/4885 |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | PTGDR, GRIN2A, PTGDR2 | ALDH1A1 826/4885HTR3E 711/4885HTR3B 329/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | ALDH1A1 1148/4885HTR3E 1510/4885HTR3B 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.